As part of a series of regular updates on developments in life sciences securities litigation (see Q3 2017 Quarterly Report), this report addresses recent activity in securities actions a...
On Friday, January 19, 2018, the Securities and Exchange Commission (SEC) announced that “should there be a federal government shutdown after January 19, the SEC will remain open for a ...
In two important recent decisions, DFC Global Corp. v. Muirfield Value Partners, L.P. and Dell Inc. v. Magnetar Global Event Driven Master Fund Ltd., the Delaware Supreme Court provided c...
The Tax Cuts and Jobs Act has now passed both houses of Congress and is expected to soon be signed into law. In this memo we address disclosure considerations for public companies that co...
On October 23, the SEC approved a new PCAOB audit standard that requires the auditor’s report to identify and discuss critical audit matters (CAMs) encountered in the audit. The new sta...
We previously highlighted the increased activity and some emerging patterns in securities litigation against life sciences companies during the first half of 2017. This report, the first...
New revenue recognition rules (ASC 606 and IFRS 15) are required to be adopted by most public companies starting January 1, 2018 and most private companies starting January 1, 2019. These...
On August 17, the SEC’s Division of Corporation Finance announced updated guidance that should reduce the time and expense for companies who are preparing to go public. Under the new gu...
We
previously outlined
the growing threat of securities class action lawsuits against life sciences companies and the importance of the United States Supreme Court’s decision in Omn...
